SIP
ZVRA icon

Stoneridge Investment Partners’s Zevra Therapeutics ZVRA Stock Holding History

Stoneridge Investment Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,788
Closed -$306K – 198
2026
Q1 		$306K Hold
32,788
– – 0.22% 85
2025
Q4 		$294K Buy
32,788
+11,659
+55% +$110K 0.2% 86
2025
Q3 		$201K Buy
+21,129
New +$212K 0.14% 97

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stoneridge Investment Partners's ZVRA Position: Q2 2026 in Review

Stoneridge Investment Partners sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 32,788 shares — an estimated $306K sold.

Stoneridge Investment Partners first reported a position in ZVRA in Q3 2025 and held it in 3 quarters. The position peaked at $306K in Q1 2026. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Stoneridge Investment Partners reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stoneridge Investment Partners sold 32,788 Zevra Therapeutics shares in Q2 2026, an estimated $306K.
  • Stoneridge Investment Partners first reported a position in Zevra Therapeutics in Q3 2025 and held it in 3 quarters.
  • Stoneridge Investment Partners's Zevra Therapeutics position peaked at $306K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.